Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZDI 694)
1998

Effects of Impaired Renal Function on Raltitrexed Pharmacokinetics

Sample size: 16 publication Evidence: moderate

Author Information

Author(s): I Judson, T Maughan, P Beale, J Primrose, P Hoskin, J Hanwell, C Berry, M Walker, F Sutcliffe

Primary Institution: Institute of Cancer Research

Hypothesis

How does mild to moderate renal impairment affect the pharmacokinetics of raltitrexed?

Conclusion

Renal impairment significantly affects the pharmacokinetics of raltitrexed, leading to increased drug accumulation and longer elimination half-life.

Supporting Evidence

  • The AUCs were greater for patients with renal impairment than for those with normal renal function.
  • Terminal half-life was longer for the renally impaired patients.
  • Adverse events were more frequent in the group with renal impairment.

Takeaway

If your kidneys don't work well, a cancer drug called raltitrexed stays in your body longer, which can be a problem.

Methodology

This was an open-label, non-randomized, parallel-group trial comparing pharmacokinetics in patients with mild to moderate renal impairment and those with normal renal function after a single intravenous dose of raltitrexed.

Potential Biases

The unequal distribution of gender in the study groups could introduce bias in the results.

Limitations

The study had an imbalance in the number of men and women in the two groups, which may confound the results.

Participant Demographics

16 adult patients with advanced solid tumors; 8 with mild to moderate renal impairment (7 women) and 8 with normal renal function (7 men).

Statistical Information

P-Value

0.002 and 0.008 for AUCs; 0.030 for terminal half-life.

Confidence Interval

95% CI 1.36-2.84 for AUCo; 1.25-3.29 for AUCo_

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication